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HLA-I molecules play a central role in antigen presentation. They
typically bind 9- to 12-mer peptides, and their canonical binding
mode involves anchor residues at the second and last positions of
their ligands. To investigate potential noncanonical binding
modes, we collected in-depth and accurate HLA peptidomics
datasets covering 54 HLA-I alleles and developed algorithms to
analyze these data. Our results reveal frequent (442 unique pep-
tides) and statistically significant C-terminal extensions for at least
eight alleles, including the common HLA-A03:01, HLA-A31:01, and
HLA-A68:01. High resolution crystal structure of HLA-A68:01 with
such a ligand uncovers structural changes taking place to accom-
modate C-terminal extensions and helps unraveling sequence and
structural properties predictive of the presence of these exten-
sions. Scanning viral proteomes with the C-terminal extension mo-
tifs identifies many putative epitopes and we demonstrate
direct recognition by human CD8+ T cells of a 10-mer epitope
from cytomegalovirus predicted to follow the C-terminal ex-
tension binding mode.
HLA-I–peptide interactions | HLA peptidomics | T cell epitope |
HLA-I structures | computational immunology
HLA class I (HLA-I) molecules play a major role in immunedefense mechanisms by presenting to T cells peptides from
the intracellular matrix. Peptides presented on HLA-I molecules
originate mainly from proteasomal degradation of self or
pathogen-derived proteins. These peptides are first translocated
to the endoplasmic reticulum. There, they can load on HLA-I
molecules provided their sequence is compatible with HLA-I
binding motifs. Peptide–HLA-I complexes are then transported
to the cell surface where they can elicit T cell recognition, pri-
marily upon presentation of nonself peptides.
Most HLA-I alleles preferentially bind 9- to 12-mer peptides
(1–5), and the majority of alleles accommodate peptides with
anchor residues at the second and last positions. From a struc-
tural point of view, anchor residues point directly into the HLA-I
peptide binding groove. Their importance for HLA-I–peptide
interactions is also reflected at the sequence level, where align-
ments of HLA-I ligands display clear specificity at the second
and last positions for most alleles. Nine-mer HLA-I ligands are
characterized by a linear binding mode. For longer peptides,
numerous crystal structures have shown the presence of a bulge
at middle positions, protruding outside of the HLA-I binding site
to accommodate the additional residues between the two anchor
positions (e.g., ref. 6).
Over the years, anecdotal evidences of C-terminal extensions
beyond the last anchor position have been observed among
HLA-A02:01 ligands and crystal structures with such ligands
were published first in 1994 (7) and later in 2009 (8). More re-
cently, analysis of HLA peptidomics data obtained by mass
spectrometry (MS) from cell lines transfected with soluble HLA-
A02:01 and infected with Toxoplasma gondii revealed several C-
terminal extensions and showed that, for this allele, C-terminal
extensions were mainly found among peptides coming from
pathogens (9, 10). X-ray crystallography revealed distinct struc-
tural mechanisms in HLA-A02:01 to accommodate C-terminal
extensions (9, 10). N-terminal extensions have also been recently
observed in HLA-B57:01 (11) and HLA-B58:01 (12). However, N-
or C-terminal extensions have not been much investigated in other
HLA-I alleles based on unbiased HLA-I ligand datasets [see some
results in mouse (15)]. As such, it remains unclear whether they
occur frequently and, if so, whether they can be recognized by
CD8 T cells, although the latter may be expected.
Here, we introduce a statistical approach to rigorously in-
vestigate N- and C-terminal extensions in large datasets of naturally
presented HLA-I ligands obtained by in-depth HLA peptidomics
profiling of cell lines and tissue samples covering more than 50
HLA-I alleles. Our work reveals widespread C-terminal extensions
for at least eight HLA-I molecules (HLA-A02:03, HLA-A02:07,
HLA-A03:01, HLA-A31:01, HLA-A68:01, HLA-A68:02, HLA-
B27:05, and HLA-B54:01), and we identify both sequence and
structural features in HLA-I alleles predictive of the presence of
C-terminal extensions. A crystal structure of HLA-A68:01 in
complex with such a ligand uncovers structural changes to ac-
commodate the C-terminal extensions. Scanning viral proteomes
with our motifs describing C-terminal extensions further enabled us
to demonstrate direct CD8 T cell recognition of an HLA-A03:01
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restricted epitope from cytomegalovirus (CMV) predicted to fol-
low the C-terminal extension binding mode.
Results
Unbiased Investigation of C- and N-Terminal Extensions. To in-
vestigate the presence of C- and N-terminal extensions in HLA-I
ligands, we collected recent pooled and monoallelic HLA pep-
tidomics datasets from seven studies covering 43 samples,
54 different HLA-I alleles, and 109,953 unique peptides (2, 13,
14, 16–19) (SI Appendix and Dataset S1). These datasets were all
generated with <1% false discovery rate and were not filtered
with any predictor. We hypothesized that C- or N-terminal ex-
tensions among naturally presented endogenous HLA-I ligands
may be determined by identifying peptides of 10 or more amino
acids that do not match motifs expected for ligands following the
bulge model (Fig. 1A). For pooled HLA peptidomics data, 9-mer
binding motifs were identified and annotated with our recent
motif deconvolution algorithm (4, 19) (Fig. 1B and SI Appendix).
Importantly, these motifs were identified without relying on
HLA-I ligand predictors and, therefore, represent a fully un-
biased view of the binding specificity of HLA-I alleles. Focusing
on the first three and the last two positions in the 9-mer motifs,
we then built position weight matrices (PWM) modeling bulges,
N-terminal extensions, or C-terminal extensions for each of the
9-mer motifs (SI Appendix). For 10-mers, bulges were modeled
by incorporating five nonspecific positions between the first
three and the last two residues. C- and N-terminal extensions
were modeled by adding four nonspecific positions in the middle
and one nonspecific position at the C and N terminus, re-
spectively (Fig. 1C and SI Appendix).
Using the three models derived from each 9-mer motif, we
then scored all 10-mer peptides (Fig. 1C and SI Appendix).
Peptides that displayed a significantly higher score for exactly
one allele and one model were assigned to this allele and the
corresponding model (SI Appendix). For monoallelic cell lines,
comparison was only performed among bulge, N- and C-terminal
extension models of the same allele. To determine statistical
significance of N- or C-terminal extensions, we developed a null
model representing the expected 10-mer HLA-I ligands assum-
ing only bulges (SI Appendix). We finally retrieved all sets of
peptides predicted to follow N- or C-terminal extensions asso-
ciated to a given allele in a given sample that passed statistical
significance (Z-score > 2). This resulted in 15 motifs of C-ter-
minal extensions (for a total of 396 unique 10-mer peptides) and
no motif of N-terminal extensions (Fig. 2A and SI Appendix, Fig.
S1). Seven motifs corresponded to C-terminal extensions asso-
ciated to HLA-A03:01 across different samples, two motifs to
HLA-A68:01 and one motif to each of the other alleles (i.e.,
HLA-A02:03, HLA-A02:07, HLA-A31:01, HLA-A68:02, HLA-
B27:05, and HLA-B54:01; Fig. 2A, SI Appendix, Fig. S2, and
Datasets S2 and S3). We first note that motifs describing C-
terminal extensions associated to the same allele (i.e., HLA-
A03:01 or HLA-A68:01) in different datasets displayed a very
high similarity among each other (rectangles in Fig. 2A). This
highlights the remarkable reproducibility of our predictions
across our very heterogeneous set of HLA peptidomics studies.
The average frequency of C-terminal extensions among 10-mer
ligands is shown in Fig. 2B.
To investigate whether C-terminal extensions may extend for
more than one amino acid, we applied our approach to longer
peptides (SI Appendix) and found statistically significant evi-
dences of C-terminal extensions for HLA-A02:07 and HLA-
B27:05 for a total of 46 unique 11-mer peptides (Fig. 2 C and D
and Datasets S2 and S3). The motifs are consistent with the 10-
mer C-terminal extensions (Fig. 2A). A trend was also observed
in some samples for HLA-A02:01, HLA-A02:03, HLA-A03:01,
HLA-A68:02, and HLA-B54:01 (Dataset S2), although it did not
pass our thresholds on the number of ligands or the Z-score.
When analyzing even longer ligands (12-mers), we did not find
anything statistically significant, but the number of such ligands
identified by MS is much smaller so that it may be difficult to
confidently identify C-terminal extensions with our approach.
Robustness to Noise. To explore the robustness of our findings
with respect to noise in HLA peptidomics data, we reran our
whole pipeline, adding 5% of randomly selected peptides from
the human proteome to all datasets. Remarkably, the predicted
C-terminal extensions remained basically unchanged (SI Ap-
pendix, Fig. S3). In particular, we did not observe any new C-
terminal extension motifs that would arise from the random
peptides. This clearly suggests that C-terminal extensions pre-
dicted in this work are not resulting from contaminations in HLA
peptidomics data.
In Vitro Validation. To experimentally test our predictions, we
selected 10-mer ligands predicted to follow the C-terminal ex-
tension binding mode for three alleles (HLA-A03:01, HLA-
A31:01, HLA-A68:01). We mutated either the last or second-to-
last residue and experimentally measured the stability of the
wild-type and the two mutated peptides (SI Appendix). 9-mer
peptides without the predicted C-terminal extensions were used
as positive controls. As expected, mutating the last residue had
little effect on their binding stability, while mutating the second-
to-last residue significantly decreased the stability (Fig. 3). These
data strongly suggest that, for these peptides, the second-to-last
residue is playing the role of the anchor residue and the last
residue is extending beyond the canonical C terminus of HLA-I
ligands. We also tested other P10 mutants that did not match the
motif predicted by our analysis. In general, the stability of these
mutants was lower than for peptides seen in MS data, especially
for HLA-A03:01 and HLA-A68:01 (SI Appendix, Fig. S4). Of
note, peptides with R or K at P10 could also form bulges, which
likely explains their higher stability. To test whether longer C-
terminal extensions may bind to HLA-A03:01, we added all
amino acids not compatible with the bulge model at the C ter-
minus of the 10-mer HLA-A03:01 ligand KLAYTLLNKL and
measured the stability of these peptides (SI Appendix, Fig. S5).
Our results indicate that most of the 11-mers did bind, although
with lower stability compared with the 10-mer peptide. This
suggests that C-terminal extensions can extend for more than
A B
C
Fig. 1. (A) General description of the pipeline developed in this work to
identify and validate N- or C-terminal extensions. (B) Example of 9-mer
motifs identified in HLA peptidomics data from Mel_15 (16). The number of
peptides assigned to each motif is shown in parentheses. (C) Illustration of
the different models built from the 9-mer motifs (bulge, C- and N-terminal
extension) to investigate noncanonical binding modes among 10-mers.
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one residue in HLA-A03:01 ligands, although this likely corre-
sponds to a small fraction of the actual HLA peptidome, as
suggested by their low frequency in MS data.
We then analyzed peptides that displayed similar scores for the
bulge and the C-terminal extension model (red circles in SI Ap-
pendix, Fig. S1). Most of them displayed the same or very similar
amino acids at P9 and P10 (Dataset S4). To investigate whether
they are more likely to adopt a bulge or a C-terminal extension
binding mode, we measured the stability of RYIEIFPSRR with
HLA-A31:01. R(9)S did not affect the binding, while R(10)S de-
creased the stability (SI Appendix, Fig. S6). This suggests that
peptides displaying similar scores for the two models may pref-
erentially adopt a bulged conformation.
Crystal Structures of C-Terminally Extended HLA-I Ligands. To in-
vestigate the structural mechanisms underlying C-terminal exten-
sions uncovered in this work, we generated a high-resolution
(1.6 Å) crystal structure of HLA-A68:01 in complex with a 10-mer
peptide (ETSPLTAEKL; Fig. 3) predicted to follow the C-ter-
minal extension binding mode (Fig. 4A and SI Appendix, Fig. S7).
As expected, the lysine at P9 (yellow sidechain) filled the F pocket
and superimposed nicely with the last residue (K9) of canonical
9-mer ligands of HLA-A68:01 (blue sidechain in Fig. 4A). More
importantly, to accommodate the C-terminal extension (L10), the
Y84 side chain was flipped by 90° and the two alpha helices
around the F pocket moved away from each other (Fig. 4A), as
measured by the distance between C-alpha atoms of residues
80 and 143 (D80–143 = 11.1 Å versus D80–143 = 10.1 Å for the
complex with a 9-mer peptide). Interestingly, the same flip had
been observed in one of the HLA-A02:01 structures in complex
with C-terminally extended ligands (9) (Fig. 4B). However, in
contrast to HLA-A02:01 where the side chain of the first residue
of the C-terminal extension points toward the solvent [K12 Fig. 4B
(9), see also L10 in PDB ID code 5FA4 and D10 in PDB ID code
5F7D (10)], in the case of HLA-A68:01, the C-terminal extension
side chain filled the pocket created by the flip of Y84 side chain
(SI Appendix, Fig. S8). This result is fully consistent with the
specificity for hydrophobic residues in the C-terminal extension
motif of HLA-A68:01 (Fig. 2A). It is also interesting to note that
the flip of Y84 side chain was recently observed in a crystal
structure of peptide-MHC-β2m in complex with TAPBPR, sug-
gesting that loading of C-terminal extensions may be favored
in vivo (20).
SI Appendix, Fig. S4 shows that the hydrophobic side chain at
P10 is not strictly required, and peptides with S or D at this
position can bind. In these cases, we anticipate that the P10 side
chain points toward the solvent, as in previous structures of
HLA-A02:01 in complex with C-terminal extensions, although
we cannot exclude that additional structural changes may further
modify the physical properties of the new pocket to accommo-
date polar or charged amino acids.
Propensity of HLA-I Alleles for C-Terminal Extensions. To investigate
the molecular determinants of C-terminal extensions, we aligned
the sequences of all HLA-I alleles considered in this work and
checked whether some amino acid patterns in residues sur-
rounding the F pocket characterize alleles predicted to accom-
modate C-terminal extensions (SI Appendix). Clear differences
were observed at specific positions (Fig. 4C) and showed overlap
with properties characterizing HLA-A alleles, as expected from
the higher proportion of HLA-A alleles predicted to display
C-terminal extensions (Fig. 2A). Interestingly, glycine is known
to destabilize alpha helices, and the presence of glycine at po-
sition 79 (i.e., exactly where the α1 helices start to be no longer
aligned in Fig. 4A) in most HLA-I alleles predicted to display
C-terminal extensions may endow the α1 helix with the flexibility
Fig. 3. In vitro binding stability assays for peptides predicted to follow the
C-terminal extension binding mode for HLA-A03:01, HLA-A31:01, and HLA-A68:01.
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Fig. 2. (A) Predicted 10-mer C-terminal extension motifs found for different
HLA-I alleles in the different datasets (see also Datasets S2 and S3). Paren-
theses indicate the number of peptides associated to each motif. (B) Esti-
mates of the frequency of C-terminal extensions among 10-mers for alleles
shown in A. (C) C-terminal extensions motifs comprising two residues after
the second anchor residue in 11-mers ligands. (D) Estimates of the frequency
of C-terminal extensions among 11-mers for alleles shown in C.
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required to accommodate such extensions. To test whether these
amino acid patterns may help predict whether an allele is more
likely to display C-terminal extensions, we trained a logistic re-
gression and performed a rigorous cross-validation (SI Appen-
dix). An average area under the ROC curve (AUC) of 0.85 could
be obtained, suggesting that alleles accommodating C-terminal
extensions may be reasonably well predicted from their se-
quence. Lower accuracy was reached in a simple model where
HLA-A alleles are predicted to display C-terminal extensions
and HLA-B/C alleles are not (AUC = 0.76). To further in-
vestigate molecular mechanisms allowing for C-terminal exten-
sions, we surveyed available X-ray structures of HLA-I alleles
considered in this work (SI Appendix, Table S1). As before, we
computed the distance D80–143 between the two alpha helices
surrounding the C terminus of canonical ligands (SI Appendix,
Table S1). Interestingly, we observed that, on average, alleles
predicted to display C-terminal extensions showed larger dis-
tances between these two helices already when interacting with
canonical 9-mer peptides (P = 0.002, Wilcoxon rank-sum test;
Fig. 4D). Using this distance to predict alleles accommodating C-
terminal extensions among those with available crystal structures
led to an AUC of 0.92. Of note, HLA-B51:01 is characterized by
much higher frequency of 8-mer ligands compared with other
HLA-I alleles (2, 3, 21). As for HLA-A01:01, we observed a trend
for C-terminal extensions in some samples (e.g., the monoallelic
cell line), but not in other samples (e.g., Melanoma/Mel_12; see SI
Appendix, Fig. S9 and Dataset S2, although most 10-mer peptides
in this sample should come from HLA-A01:01 since HLA-
B08:01 and HLA-C07:01 poorly bind 10-mers). We finally point
out that the clear patterns in both sequence and structural prop-
erties of HLA-I alleles predicted to display C-terminal extensions
provides an additional and independent validation of our predic-
tions in Fig. 2 based only on HLA peptidomics data.
Explicitly Incorporating C-Terminal Extensions in HLA-I Ligand Predictors.
C-terminal extensions have not been routinely investigated in pre-
vious studies and the training set of most existing HLA-I ligand
predictors typically does not include them, even if the recent ver-
sion of NetMHC tools can mathematically handle them (5, 22, 23).
We therefore retrained our predictor MixMHCpred (19) using
multiple PWMs to model C-terminal extensions (24) (SI Appendix).
To validate our algorithm, we took advantage of the fact that HLA-
A03:01 and HLA-A68:01 alleles were present in multiple datasets
and attempted to repredict all of the 10-mer peptides of these
datasets, excluding data from the dataset used for testing in the
training of our predictor (SI Appendix). As negative data, we in-
cluded fourfold decoy (i.e., 10-mers randomly selected from the
human proteome) and computed both the positive predictive value
corresponding to the top 20% predictions and the AUC (SI Ap-
pendix). We observed that explicitly modeling C-terminal extensions
increased the performance compared with the previous version of
our predictor (MixMHCpred1.0) (19), as well as other widely used
HLA-I ligand predictors that did not include unbiased MS data in
their training set (22, 23) (Fig. 5A and SI Appendix, Fig. S10). The
improvement came mainly from higher scores for ligands displaying
C-terminal extensions, as shown in Fig. 5B for the HLA-A03:01 10-
mer ligands isolated from a monoallelic cell line (2) (P = 1.0 × 10−7,
Wilcoxon signed-rank test).
A
C D
B
Fig. 5. (A) Benchmarking of our HLA-I ligand predictor (MixMHCpred1.1).
The y axis shows the positive predictive value among the top 20% of the
predictions. (B) Analysis of scores when explicitly modeling C-terminal exten-
sions (MixMHCpred1.1) or not (MixMHCpred1.0) for the 10-mer HLA-A03:01
ligands from a monoallelic cell line (2), as a function of the C-terminal amino
acids (P9 and P10). (C) IFN-γ–ELISpot results obtained by stimulation with a
C-terminally extended 10-mer HLA-A03:01 ligand (TVRSHCVSKI, from CMV,
Left) vs. no peptide (Right) of a PBMC sample from a HLA-A03:01 and CMV
seropositive healthy donor. (D) Multimer analysis of CD8 T cells from a healthy
donor recognizing the HLA-A03:01 restricted C-terminally extended 10-mer
peptide TVRSHCVSKI (Left) and the negative control (RVRAYFYSKV/HLA-
A03:01 tetramer) for which we did not observe T cell recognition (Right).
A B
C
D
Fig. 4. (A) New crystal structure of HLA-A68:01 (white ribbon) in complex with
a C-terminally extended ligand (yellow) superimposed with HLA-A68:01 (green
ribbon) in complex with a canonical 9-mer ligand (blue, PDB ID code 4WHZ) (29).
(B) Comparison of HLA-A68:01 (white ribbon) in complex with a C-terminally
extended ligand (yellow) and the complex of HLA-A02:01 (pink ribbon) bound
to a C-terminal extended 12-mer peptide (FVLELEPEWTVK, magenta, PDB ID
code 5DDH) (9). (C) HLA-I residues surrounding the C terminus of canonical li-
gands and displaying the largest Jensen–Shannon divergence between alleles
with C-terminal extensions (Top Left) and alleles without C-terminal extensions
(Bottom Left). For comparison, the sequence logos of HLA-A (Top Right) and
HLA-B/C (Bottom Right) alleles at the same positions are displayed. (D) Analysis
of the distance D80–143 for alleles with available crystal structures (SI Appendix,
Table S1). Green lines correspond to alleles displaying C-terminal extensions. The
orange line represents HLA-A02:01.
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Almost no difference betweenMixMHCpred1.0 andMixMHCpred1.1
could be observed when testing our algorithm on other datasets
used in previous benchmarking studies. However, we anticipate
that C-terminal extensions are very rare in these datasets since
most of the known HLA-I ligands had been first predicted with
former versions of HLA-I ligand predictors. For instance, when
analyzing immune epitope database (IEDB) data (25) for HLA-
A03:01 ligands coming from earlier studies than those consid-
ered in this work, we could not see any statistical evidence of C-
terminal extensions, suggesting that such ligands had not been
tested in binding assays, or had been filtered in MS data.
Identification of Immunogenic C-Terminally Extended Epitopes. To in-
vestigate the immunological relevance of HLA-I ligands displaying
C-terminal extensions, we used our predictor and scanned both
human cancer testis antigens and viral proteomes with the motifs
characterizing 10-mer C-terminal extensions for HLA-A03:01 and
HLA-A68:01 (SI Appendix). This analysis revealed many putative
epitopes, including peptides from the PRAME cancer testis anti-
gen and several CMV, Epstein–Barr virus (EBV), HIV, human
papillomavirus (HPV), influenza, and yellow fever peptides (Table
1). We measured the binding stability of these peptides and found
values falling within the range of CD8 T cell epitopes (Table 1).
We then focused on one CMV peptide binding to HLA-A03:01
and predicted to follow the C-terminal extension binding mode
(TVRSHCVSKI, asterisk in Table 1). We stimulated a peripheral
blood mononuclear cells (PBMCs) sample from a healthy donor
(both HLA-A03:01 and CMV seropositive) with the 10-mer
peptide for 12 d (Materials and Methods). Subsequently, we ob-
served cytokine production by IFN-γ–ELISpot after rechallenge
with the CMV 10-mer peptide for 16 h (Fig. 5C), suggesting that
this epitope is potentially immunogenic in humans. To determine
whether CD8 T cells could directly recognize the C-terminally
extended 10-mer peptide, we constructed HLA-A03:01 tetramers
loaded with the 10-mer peptide (Materials and Methods). Ana-
lyzing CD8 T cells with such tetramers revealed a population
of CD8 T cells that directly bound to the 10-mer peptide/HLA-
A03:01 complex (Fig. 5D). The IFN-γ–ELISpot, tetramer and
refolding assays were repeated using the K(9)L and I(10)L mu-
tants, and the truncated 9-mer (TVRSHCVSK) (SI Appendix, Fig.
S11 A–C). In all cases, we could detect IFN-γ production after
stimulation (SI Appendix, Fig. S11A). Tetramer analysis revealed
that T cells directly interacting with each of these epitopes could
be identified, although the responses were not very strong (SI Ap-
pendix, Fig. S11B). The 9-mer (TVRSHCVSK) displayed the stron-
gest binding stability which, together with the preference of K/R of
HLA-A03:01 at the second anchor position, suggests that the 10-mer
CMV epitope follows the predicted C-terminal extension binding
mode (SI Appendix, Fig. S11C). However, we also observed residual
binding of the K(9)L mutant (similar to what was observed in Fig. 3
for the first P9 mutant). To provide further evidence that the 10-mer
CMV epitope follows the C-terminal extension binding mode, we
tested the cross-reactivity of T cells with the 10- and 9-mer peptides
(SI Appendix). We observed that T cells recognizing the 10-mer
peptide were all cross-reactive with the 9-mer peptide (SI Appendix,
Fig. S11D). This level of cross-reactivity is expected with C-terminal
extensions since residues in contact with the T cell receptor (TCR)
are structurally conserved but is not expected with bulging 10-mers.
Altogether these results suggest that TVRSHCVSKI follows the
predicted C-terminal extension binding mode and that C-terminally
extended peptides can form bona fide CD8 T cell epitopes.
Discussion
MS analysis provides an unbiased view of HLA-I ligands that is
not restricted by a priori assumptions on HLA-I binding speci-
ficity. Here, we capitalized on this premise to explore non-
canonical binding modes of HLA-I ligands. Of the 54 alleles
considered in this work, we found clear statistical evidences of
C-terminal extensions for 8 of them and validated these pre-
dictions at the biochemical and structural level for some of fre-
quent alleles in Caucasian populations.
In addition to providing evidence of C-terminal extensions, our
work enabled us to characterize motifs describing this noncanonical
binding mode. We observed that the C-terminal extensions are often
characterized by the presence of hydrophobic residues. We also note
that, for three of eight alleles (i.e., HLA-A03:01, HLA-A31:01, and
HLA-A68:01), a positively charged residue is found at the second
anchor. This positively charged residue interacts with D77 and
D116 in our HLA-A68:01 structure, which is consistent with the fact
that D is preferentially observed at these positions in alleles predicted
to accommodate C-terminal extensions (Fig. 4C). The distinct binding
specificity between the anchor residue and the C-terminal extension
makes these cases especially amenable for the sequence-based model
that we developed. However, the majority of alleles show preference
for hydrophobic residues at the second anchor position. In these
cases, and assuming that the preference for hydrophobic residues at
the C-terminal extension is conserved, sequenced-based algorithms
cannot unambiguously determine whether a 10-mer peptide with two
hydrophobic amino acids at the last two positions follows the bulge or
the C-terminal extension binding mode. Moreover, we anticipate that
competition with high-affinity 9-mer ligands may mask cases of lower-
affinity C-terminal extensions in HLA peptidomics data (e.g., pep-
tides with only one good anchor residue). Therefore, our estimate of
the number of alleles that accommodate C-terminal extensions cor-
responds to a lower bound, and we cannot exclude that this non-
canonical binding mode may be observed in other alleles. In
particular, some C-terminal extensions among HLA-A02:01 ligands
may be present in our data with two hydrophobic residues at the last
positions. Nevertheless, the smaller distance between the two alpha
helices of HLA-A02:01 (Fig. 4D) suggests that C-terminal extensions
for this allele should be rarer or involve other mechanisms like cross-
presentation (9, 10). Along this line, we note that statistically signifi-
cant C-terminal extensions are identified by our algorithm in the set
of T. gondii HLA-A02:01 ligands (9) (SI Appendix, Table S2).
Finally, we stress that contaminations from coeluting or wrongly
identified peptides, as well as challenges in aligning small peptides
or in the deconvolution of pooled HLA peptidomics datasets, can
easily result in cases that look like N- or C-terminal extensions.
This is the reason why we developed the statistical framework
described in this work and tested the robustness of our predictions
with respect to noise.
Table 1. Binding stability (half-lives) of C-terminally extended
HLA-I ligands from cancer testis antigens and viral proteins
Allele Organism Protein Sequence Half-life, h
A03:01 HIV_B VPU RLIDRLIERA 19.8 ± 2.0
A03:01 Influenza NCAP RMCNILKGKF 34.2 ± 3.0
A03:01 Y. Fever POLG RMGERQLQKI 30.0 ± 3.0
A03:01 HCMV UL44 TLLNCAVTKL 14.7 ± 0.3
A03:01 HCMV UL44 TVRSHCVSKI* 16.6 ± 3.1
A03:01 EBV BRLF1 RVRAYTYSKV 51.6 ± 10.0
A03:01 EBV BNRF1 RTWDRMTEKL 27.5 ± 0.8
A03:01 HIV NEF QVPLRPMTYKA 48.1 ± 12.2
A03:01 HIV NEF QVPLRPMTYKG 31.9 ± 7.9
A03:01 Human PRAME RLWGSIQSRY 19.9 ± 12.0
A68:01 Human PRAME ETLSITNCRL 14.5 ± 6.2
A68:01 HCMV UL82 EAASGSFGRL 81.7 ± 14.6
A68:01 HCMV HELI EVVQRGLSRL 16.6 ± 0.8
A68:01 HPV16 E1 ETIEKLLSKL 12.9 ± 5.8
A68:01 EBV BPLF1 ETVADWKRRL 22.3 ± 1.4
A68:01 Y. Fever POLG QTSRLLMRRM 19.3 ± 2.0
*The peptide used in the IFN-γ–ELISpot andmultimer analyses of Fig. 5 C andD and
SI Appendix, Fig. S11. Bold letters indicate the predicted second anchor residue.
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Despite these inherent limitations of sequence-based approaches,
it is likely that several alleles show very few, if any, C-terminal ex-
tensions. For instance, six alleles from our list showed specificity at
the last anchor residue that is not restricted to hydrophobic amino
acids (SI Appendix, Fig. S12), but we did not see any trend of C-
terminal extensions among their 10-mer ligands (Dataset S2).
Our model also incorporated the possibility to have N-terminal
extensions, but we did not find any such event, although N-terminal
extensions have been recently reported (11, 12). Inspection of
existing structures of HLA-I molecules in complex with 9-mer
peptides shows that the C-terminal carboxyl group of 9-mer HLA-I
ligands is often partly solvent exposed. Conversely, the N-terminal
amide group points in general toward the binding site. This likely
explains why N-terminal extensions appear to be much less fre-
quent, although we cannot exclude that our approach may miss
some N-terminal extensions if the specificity at P2 is the same as at
P3 in the N-terminally extended ligands. Interestingly, this appears
to be the case for N-terminal extensions reported for HLA-
B57:01 and may explain why these extensions could not be easily
detected with sequence-based approaches and have been first
identified by X-ray crystallography (11).
Our demonstration of direct recognition by human CD8 T cells
of a peptide predicted to follow the C-terminal extension binding
mode indicates that these extensions are compatible with TCR
binding. This did not come as a surprise since amino acids in contact
with the TCR (typically positions 4–7) are structurally conserved
between 9-mers and C-terminally extended 10-mers, which is con-
sistent with the cross-reactivity observed in SI Appendix, Fig. S11D.
Moreover, the vast repertoire of TCR enables recognition of many
different types of epitopes (e.g., bulges, posttranslational modifica-
tions), so that the small changes in the positioning of the two alpha
helices were not expected to prevent TCR recognition. C-terminal
extensions may further play a role in the binding of KIR proteins,
which are known to recognize amino acids surrounding the C ter-
minus of canonical HLA-I ligands (11, 26, 27). Along these lines, we
note that the HIV peptides in Table 1 represent a known escape
mutant (NEF A83G), which was previously proposed to act at the
level antigen processing (28). Our results suggest that this mutation
may also have an effect on recognition of peptide–HLA complexes
by NK receptors. As such, we anticipate that inclusion of C-terminal
extensions in our HLA-I ligands predictor may help uncovering new
CD8 T cell epitopes in viruses or tumors, as well as potential targets
of NK cells.
Overall, our results reveal frequent C-terminal extensions in at
least 8 of the 54 HLA-I alleles analyzed in this study and high-
light the power of unbiased HLA peptidomics data together with
new algorithms to unravel properties of HLA-I molecules. Our
evidence of direct T cell recognition of such epitopes suggests
that C-terminal extensions may be clinically relevant for in-
fectious diseases or cancer immunotherapy.
Materials and Methods
Binding stability measurements were performed with standard refolding
assays, and stable complexes were detected with ELISA. X-ray crystallography
was carried out as described in SI Appendix. The model and structure factors
have been deposited with PDB ID code 6EI2. PBMCs were peptide stimulated
in vitro for 12 d in the presence of 100 U/mL IL-2. Subsequently, the Elispot
was performed using the ELISpotPRO kit for Human IFN-γ from MABTECH.
CD8 T cells of the CMV 10-mer peptide stimulated PBMC were stained with a
PE-labeled HLA-A03:01/TVRSHCVSKI multimer and costained with anti-
CD8 antibody (BC A94683). Multimer+ CD8+ T cells were analyzed at the BD
ARIA III instrument equipped with the FACS Diva software.
The code for identifying C- and N-terminal extensions (MHCpExt) and the
new version of the predictor (MixMHCpred1.1) are available at https://github.
com/GfellerLab, and algorithmic details about the methods are available in
SI Appendix.
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